Drugs / TAK-418
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04202497 | Dec 2019 → Mar 2020 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT03501069 | May → Dec 2018 | — | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03228433 | Jul 2017 → May 2018 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04202497 ↗ |
| Action | Inhibit | “TAK-418 is a novel LSD1 inhibitor” PMID 33990969 ↗ Jun 2021 |
| Modality | Small molecule | “TAK-418, a novel LSD1 small molecule inhibitor” PMID 42397656 ↗ Jul 2026 |
| Route | Oral | “single oral doses” NCT03228433 ↗ |